Perimenopause With POTS, MCAS or hEDS: What Changes and What to Track

🌙 You have spent years learning your own pattern. Then somewhere in your forties the pattern stops holding. The flares arrive in a different rhythm, joints that were manageable start giving way, and the thing that used to work for three days works for one.

🧩 And every door you knock on sends you to the other one. The menopause clinic treats the hot flushes and does not know what MCAS is. The rheumatologist knows hypermobility and does not do hormones. Somewhere in between is the question you actually have, which is whether this is perimenopause, your condition, or both at once.

💚 Here is what two patient organisations in this space report, in their own words. And here is the part most articles skip: how thin the evidence underneath it still is.

⚠️ Start here: the evidence is thin, and you should know that first

Almost everything written about hormones and these conditions is written with more confidence than the research supports. Both organisations say so themselves, which is the main reason to trust them.

The Hypermobility Syndromes Association states that currently there is very little research in this space, and describes the evidence base for supplements and lifestyle changes as mostly anecdotal or hypothetical. On hormone replacement therapy and hypermobility symptoms, it says a lot more research is needed in this area.

Mast Cell Action puts it in one sentence: the connection between hormones and MCAS is under-researched.

So what follows is not a mechanism anyone has proven. It is a set of reported patterns. That distinction matters enormously when you walk into an appointment, because a clinician who hears you state a theory as fact will discount everything after it. A clinician who hears you describe your own three months of data will not.

One demarcation before we go on. If your question is about the monthly rhythm rather than the transition out of it, that is a different article: see POTS and your period for the cycle-level version of this.

🦴 What hormones appear to do to connective tissue

The HMSA's account runs roughly as follows.

Oestrogen and progesterone both play a role in collagen production, and oestrogen may also influence joint lubrication and reduce inflammation. The association says studies have indicated that oestrogen levels can affect joint laxity, particularly during pregnancy and post-menopause, when oestrogen levels decline sharply.

Progesterone has its own effects. High levels of progestogen appear to be associated with increased joint laxity, and progesterone has muscle-relaxing properties, which the HMSA notes may affect exercise performance and coordination. It may also have an indirect influence on bone remodelling.

Relaxin alters the properties of cartilage and tendons by activating collagenase, and induces an additional joint-loosening effect during pregnancy.

Testosterone gets less attention than it deserves here. The HMSA says testosterone plays a key role in muscle mass and connective tissue strength, and that lower levels of testosterone can lead to decreased muscle tone and further instability of hypermobile joints. Separately, Mast Cell Action notes that testosterone levels drop in women starting in their late twenties, so this is a slow slope rather than a cliff.

The practical upshot, in the HMSA's own framing, is that many hypermobile women report worsening of symptoms during specific hormonal phases, the ones it names being menstruation, pregnancy and perimenopause.

🔥 What hormones appear to do to mast cells

Mast Cell Action says it has been reported that more women than men have MCAS, and that many women experience symptoms particularly around hormonal changes, such as puberty and perimenopause. It is careful to present that as reported rather than established.

Two directions are described. High oestrogen spikes can trigger mast cells to release various active substances, histamine and inflammatory mediators among them. And in the early stages of perimenopause, progesterone levels drop, which the organisation says affects the body's ability to calm mast cells.

Which is why perimenopause specifically, rather than menopause, is often the rough part. It is not a steady decline. It is significant hormonal fluctuation, and fluctuation is the thing mast cells appear to object to.

Stress is listed as a compounding factor, with the body shifting into a fight or flight state that the organisation says exacerbates histamine release and inflammatory responses. Worth noting if your forties happen to also contain teenagers, ageing parents or a job.

Again, for the monthly version of this pattern rather than the transitional one, we have MCAS and your cycle.

🪞 Why this is so genuinely hard to tell apart

Look at the two symptom lists side by side and the problem is obvious. Fatigue. Poor sleep. Palpitations. Brain fog. Temperature dysregulation. Joint pain. Mood changes. Every one of them belongs to both columns.

The HMSA makes the point that symptoms during these life stages can overlap with hypermobility symptoms, and that the combination of the two causes can amplify the severity of the symptoms. That is the honest answer to the question of which one it is: frequently both, interacting.

One concrete example of the overlap, from Mast Cell Action: overactive bladder is a common symptom of perimenopause due to hormone changes. If you have spent years attributing bladder symptoms to your condition, that is a useful thing to re-examine rather than assume.

And one more, from Mast Cell Action, flagged with its own caveat: Long Covid can affect hormone production and exacerbate perimenopausal symptoms, potentially bringing it forward. The organisation adds that there is still limited research into this. Given how many people in this community acquired their diagnosis post-virally, it is worth knowing the hypothesis exists without treating it as settled.

📊 What to track, so the answer is yours rather than a guess

Since nobody can resolve this from a blood test and a conversation, the only thing that will move the discussion forward is your own record. Our own rule of thumb, rather than anybody's published advice, is that three months is the minimum useful window, because the defining feature of perimenopause is variability, and one month tells you nothing about variability.

What is worth logging, specifically:

• Cycle dates, for as long as you still have them. Including the length, not just the start. Changing cycle length is itself information, and Mast Cell Action notes that changes in cycles often normalise over time.

• Flare days, scored, not described. A number you can plot beats a sentence you cannot.

• Joint events separately from pain. Subluxations, giving way, and new instability in a joint that was previously fine. This is the column that tells a rheumatologist something a pain score does not.

• Sleep, temperature and bladder. The three that get attributed to the wrong cause most often.

• What you changed, and when. Every supplement, dose change and new product, dated. Without this column, a flare three weeks into something new is unattributable.

Our guide to what to track daily covers how to do this without it becoming a second job, which matters, because a tracking system you abandon in week two is worse than none.

💬 What tends to be offered, and the questions to raise

Treat this section as vocabulary for a conversation, not as a plan. Every one of these is a decision for a clinician who knows your history, and the two organisations differ in emphasis precisely because the evidence is weak.

What Mast Cell Action reports. On HRT, that it is worth introducing gradually, sometimes starting with progesterone alone, and that antihistamines and mast cell stabilisers used alongside HRT can be beneficial. It notes that natural progesterone is different from synthetic versions and says it can help stabilise mast cells. On testosterone, that while there is limited research it can help some women during menopause, but that it may cause flares in others, and it suggests trialling it cautiously with a low starting dose, increasing gradually. Vaginal oestrogen is mentioned for overactive bladder symptoms. Dietary support, supplements, probiotics and stress reduction such as breathwork and ensuring regular breaks are also listed.

What the HMSA reports, and it is pointedly more cautious. That HRT and contraceptive management can be used to support symptom management, especially in post-menopausal women, but that hormones given to the body may worsen hypermobility symptoms. That progesterone-only contraception worsening symptoms is quite common among hypermobile people, and that where it does, it may be best to find an alternative. That research suggests combined pills may impact joint stability, particularly in individuals with hypermobility. And that finding the right approach may take trial and error, and support from a relevant health care professional.

Notice the tension. One organisation describes progesterone as potentially mast cell stabilising. The other describes high progestogen as associated with increased joint laxity. If you have both conditions, those two statements point in opposite directions, and nobody currently knows how to weigh them for an individual. That is not a flaw in the article. It is the actual state of the field, and knowing it is what stops you from being blindsided when the first approach does not work.

Two practical questions worth bringing, whichever route is proposed: what would tell us this is working, and by when, and what would tell us to stop. An agreed review date turns trial and error into a plan.

One suggestion you can consider without a prescription, with a note about where it comes from: the HMSA says it may be worth considering increased joint support of problematic joints when exercising, and adapting exercise routines. It makes that suggestion about the days around menstruation rather than about the menopausal transition, so treat it as a principle worth testing at this stage rather than as advice written for it.

🚩 Four claims to be careful with

This field attracts confident content. Four things are worth holding at arm's length.

• "Oestrogen dominance." Mast Cell Action notes directly that the term is not recognised by the British Menopause Society. You will see it used a great deal online. Using it in an appointment will cost you credibility.

• The PCOS connection. On PCOS, excess oestrogen and MCAS, Mast Cell Action says more research is needed to confirm any direct link.

• Stopping HRT causing flares. The organisation's position is that this is possible but not certain. What it suggests alongside that is gradual reduction of HRT and a focus on self-care to mitigate flares, with annual reviews with your doctor.

• Anything citing a precise prevalence figure. If the relationship is under-researched, a confident percentage has to have come from somewhere other than the research.

❓ Frequently asked questions

📚 Sources & further reading

The information in this article is drawn from the following sources. We encourage you to explore them.

• Mast Cell Action: Women's Health and MCAS

• Hypermobility Syndromes Association: Hormones and hypermobility